Related Experiment Video
Updated: Jun 6, 2026

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
High correlation of HPSEC-MALLS-based viral particle quantification to infectivity enables quality-by-design for
Zhengjun Li1, Xinyu Jia2, Boyu Xie1
1State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
None:
Traditional viral titer methods (e.g., TCID₅₀) are activity-based and time-consuming, limiting rapid process development and quality by design (QbD) for viral vector production. Here, using recombinant vesicular stomatitis virus (rVSV) as a model, we established a method based on high performance size exclusion chromatography coupled with multi angle laser light scattering (HPSEC -MALLS) to simultaneously monitor viral particle concentration and purity. Importantly, the physical particle concentration measured by HPSEC-MALLS correlated strongly with biological infectivity (TCID₅₀), yielding an R² of 0.975. Leveraging this correlation, we achieved real-time quality control across downstream and upstream processes. During the upstream culture stage, a multiplicity of infection (MOI) of 0.1 maximized particle production. For purification, Capto Core 700 multimodal chromatography achieved 83.53% particle recovery while removing >99% of host cell proteins and nucleic acids. In formulation studies, sucrose preserved 95.20% particle stability after five weeks at 4 °C, whereas trehalose yielded 94.92% retention following lyophilization. This HPSEC-MALLS platform enables rapid, label-free, multi parameter quality control throughout the entire viral vector process, accelerating both process optimization and clinical translation.
More Related Videos
08:07Profiling of Surface Protein Epitopes on Viral Particles by Multiplex Dual-Reporter Strategy
Published on: January 12, 2024
08:10Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
Published on: January 15, 2020